Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Digital health perspective: Chris Boyer

Leading hospital website and social media expert Chris Boyer speaks with pharmaphorum on website optimisation. Following on from our ‘Social pharma faces’ series, we’ve decided to broaden the scope of the people we speak with to encompass...

Articles

Open access in medical journals

In our medical communications themed month, pharmaphorum speaks with former editor-in-chief of the BMJ, Richard Smith, on the open access model of journal publishing and the changes he’s noted in journal publishing throughout his career. Richard Smith worked at the BMJ for 25 years during which time he served as editor-in chief for 13 years. Throughout his career he...

Articles

Clinical trials and tribulations in Latin America

Luke Sewell provides an overview of clinical trials within Latin America, explaining both the advantages and disadvantages in this region. The outsourcing of clinical trials to developing regions, given the ever growing cost associated with...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital